Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas. METHODS: Elaris UF-EXTEND was a phase 3 extension study that evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, James A., Al-Hendy, Ayman, Archer, David F., Barnhart, Kurt T., Bradley, Linda D., Carr, Bruce R., Dayspring, Thomas, Feinberg, Eve C., Gillispie, Veronica, Hurtado, Sandra, Kim, JinHee, Liu, Ran, Owens, Charlotte D., Muneyyirci-Delale, Ozgul, Wang, Alice, Watts, Nelson B., Schlaff, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Contents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253187/
https://www.ncbi.nlm.nih.gov/pubmed/32459423
http://dx.doi.org/10.1097/AOG.0000000000003869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253187/
https://www.ncbi.nlm.nih.gov/pubmed/32459423
http://dx.doi.org/10.1097/AOG.0000000000003869

Ejemplares similares